公司管理层任命 - Altimmune公司任命Christophe Arbet-Engels博士为首席医疗官，自2025年10月1日起生效 [1] - 新任首席医疗官拥有超过30年的行业、学术界和私人执业经验，将领导pemvidutide的临床开发，包括计划中的MASH三期试验 [1] - 前任首席医疗官Scott Harris博士将作为高级战略顾问留任至2026年2月 [1] 新任首席医疗官的背景与经验 - 新任首席医疗官在X4 Pharmaceuticals任职期间，为2024年获批用于WHIM综合征的Xolremdi（mavorixafor）的成功监管流程做出了广泛贡献，并领导了mavorixafor治疗慢性中性粒细胞减少症的后期临床项目 [2] - 其职业生涯早期曾在Biogen、勃林格殷格翰、罗氏、默克研究实验室等多家公司担任高级医学和临床职位，领导了包括LANTUS®和JARDIANCE®在内的多种产品的临床开发、注册、上市和生命周期管理工作 [2] - 新任首席医疗官持有法国巴黎大学的内科和内分泌学/代谢医学博士和博士学位，并完成了罗格斯大学的MBA学位 [2] 公司核心产品管线 - Altimmune是一家后期临床阶段的生物制药公司，专注于开发用于肝脏和心血管代谢疾病的新型肽类疗法 [6] - 公司的核心产品候选药物是pemvidutide，一种GLP-1/胰高血糖素双受体激动剂，用于治疗MASH、酒精使用障碍、酒精相关肝病和肥胖症 [6] - pemvidutide在MASH领域的IMPACT试验即将获得48周数据，同时正在进行酒精使用障碍和酒精相关肝病的二期试验 [2] 管理层股权激励 - 作为任命的一部分，新任首席医疗官将获得总计45万股普通股期权和15万股限制性股票单位（RSU） [3] - 期权行权价将基于2025年10月1日公司普通股的收盘价确定 [3] - 期权和RSU将分四年归属，其中四分之一在授予日一周年时归属，其余部分在此后按月或按年分期归属 [4][5]

案件背景 - 罗森律师事务所提醒在2023年8月10日至2025年6月25日期间购买Altimmune公司(NASDAQ: ALT)证券的投资者注意2025年10月6日的重要首席原告截止日期 [1] - 投资者可能无需支付任何自付费用即可通过风险代理收费安排获得补偿 [1] 诉讼程序 - 投资者可通过指定网址https://rosenlegal.com/submit-form/?case_id=22535或致电866-767-3653联系Phillip Kim律师参与集体诉讼 [2][5] - 首席原告需在2025年10月6日前向法院提出动议 其作为代表方指导诉讼程序 [2] - 在集体认证完成前 投资者需自行聘请律师或选择不作为 [6] 律师事务所资质 - 罗森律师事务所专注于证券集体诉讼和股东派生诉讼 在全球代表投资者 [3] - 2017年该律所证券集体诉讼和解数量被ISS证券集体诉讼服务评为第一 2013年以来每年排名前四 [3] - 2019年单独为投资者追回4.38亿美元 累计追回数亿美元 [3] - 创始合伙人Laurence Rosen于2020年被law360评为原告律师界泰斗 [3] 案件核心指控 - 被告在集体诉讼期间制造了拥有Altimmune公司IMPACT Phase 2b MASH试验结果的可靠信息的虚假印象 [4] - Altimmune公司未能达到纤维化减少主要终点的统计学显著性标记 但持续吹捧对顶线结果的过高预期 [4] - 公司隐瞒安慰剂组更高反应率 该情况已知或应知会对顶线结果产生负面影响 [4] - 真实细节披露后投资者遭受损失 [4]

Accessibility StatementSkip Navigation PHILADELPHIA, Sept. 25, 2025 /PRNewswire/ -- Berger Montague PC is investigating claims under the federal securities laws against Altimmune, Inc. (NASDAQ: ALT) ("Altimmune" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for obesity and liver disease, including MASH (metabolic dysfunction-associated steatohepatitis) after a class action lawsuit was filed against Altimmune. Investor Deadline: Investors who purchased ...

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between August 10, 2023 and June 25, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/altimmune-inc-lawsuit-subm ...

NEW YORK, Sept. 25, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/altimmune-inc-loss-submission-form-2/?id=168865&from=4 CLASS PERIOD: August 10, 2023 t ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Altimmune (ALT) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Altimmune between August 10, 2023 and June 25, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- What’s Happening: ...

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025 (the “Class Period”), of the important October 6, 2025 lead plaintiff deadline. SO WHAT: If you purchased Altimmune securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Altimmune class acti ...

James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. According to the complaint, on June 26, 2025, Altimmune published a press release announcing topline results from the IMPACT Phase 2b MASH trial of Pemvidutide in the Treatment of MAS ...

GAITHERSBURG, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: Stifel 2025 Virtual Cardiometabolic ForumTuesday, September 30, 2025Fireside Chat at 10:30 a.m. Eastern Time H.C. Wainwright Liver Disease Virt ...

NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between August 10, 2023 and June 25, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/altimmune-inc-lawsuit-subm ...